The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Subscribe To Our Newsletter & Stay Updated
